Nav1.7 entered the scene a decade ago as a pain target with wide-ranging analgesic effects, but it has been difficult to selectively target. Now, a team at Duke has succeeded with an antibody that blocks the channel in a closed state. The team is developing the antibody for pain and pruritus.